View Single Post
Old 06-01-2017, 12:43 AM   #7
Pamelamary
Senior Member
 
Pamelamary's Avatar
 
Join Date: Apr 2012
Location: Melbourne, Australia
Posts: 494
Re: Dose Finding Study of Subcutaneous Pertuzumab

Marie,
Your experience is interesting. My oncologist hasn't been keen on my moving to subcut Herceptin - maybe now I can guess why. She has spoken about the "one size fits all" dosage and hasn't been happy with the available data. Hope you can get back on Herceptin without the heart problems. It is a relatively easy regime, though when I think about being due for cycle 82, my eyes roll.
Best wishes..... Pam
__________________
Diagnosed 2004: Lumpectomy - 2 tumours, both grade 1 infiltrating duct carcinoma, about 12mm. ER+,
C-erbB-2 status 3+.
Clear margins, no nodal involvement.
Radiotherapy, i year Tamoxifen, 4 years Arimidex.
Rediagnosed 2012: Multiple bone metastases.
3/12: began on Marianne trial - T-DM1 + Pertuzamab/Placebo.
5/12:Unexpected development of numerous bilateral liver mets. Came off trial.
Started Docetaxol/ Herceptin + Zometa.
8/12:Bones stable +major regression in liver (!)
9/12:Can't take any more Docetaxol! Start on Herceptin and Tamoxifen. Cross fingers!
Changed to Denosumab.
11/12: Scan shows stable - yay!
11/13: Still stable :-) !!!
1/16: All stable, but lowered calcium, so switched to Zometa 3 monthly.
2/19: Happily still stable on Herceptin, Letrozole and 3 monthly Zometa.
Pamelamary is offline   Reply With Quote